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Dopamine receptors (DRs) are class A G-Protein Coupled Receptors 
(GPCRs) prevalent in the central nervous system (CNS). These 
receptors mediate physiological functions ranging from voluntary 
movement and reward recognition to hormonal regulation and 
hypertension. Drugs targeting dopaminergic neurotransmission have 
been employed to treat several neurological and psychiatric disorders, 
including Parkinson's disease, schizophrenia, Huntington's disease, 
attention deficit hyperactivity disorder (ADHD), and Tourette's syndrome. 
In vivo, incorporation of GPCRs into lipid membranes is known to be key 
to their biological function and, by inference, maintenance of their tertiary 
structure.  A further significant challenge in the structural and 
biochemical characterization of human DRs is their low levels of 
expression in mammalian cells. Thus, the purification and enrichment of 
DRs whilst retaining their structural integrity and function is highly 
desirable for biophysical studies. A promising new approach is the use of 
styrene–maleic acid (SMA) copolymer to solubilize GPCRs directly in 
their native environment, to produce polymer-assembled Lipodisqs 
(LQs). We have developed a novel methodology to yield detergent-free 
D1-containing Lipodisqs directly from HEK293f cells expressing wild-type 
human dopamine receptor 1 (D1). We demonstrate that D1 in the 
Lipodisq retains activity comparable to that in the native environment and 
report, for the first time, the affinity constant for the interaction of the 












Keywords: GPCR, Dopamine receptor, Lipodisq, Microscale 







1. We report for the first time the extraction and purification of a 
wild-type human GPCR from its native lipid environment via 
detergent-free Lipodisq formation.  
2. We demonstrate that microscale thermophoresis can be 
successfully employed to characterize ligand binding to a Lipodisq-
embedded protein. 
3. We show for the first time the binding of the neurotransmitter 
neurotensin to D1, an interaction that might have important 













GPCRs are seven transmembrane proteins and constitute the largest 
class of cell surface receptors, comprising approximately 4% of the 
human genome[1]. In humans, approximately 400 GPCRs are known to 
bind endogenous ligands and approximately 500 GPCRs are responsible 
for either olfaction or taste[2]. The heterogeneity of these GPCRs and 
the conformations they can adopt ensures the broad recognition of 
multiple external stimuli such as taste, smell, light, pain or internal stimuli 
such as hormone secretion or neurotransmission[3,4]. Due to their 
participation in nearly all cellular signalling events, they are of major 
interest to the pharmaceutical industry, with approximately 40% of all 
current marketed drugs acting as modulators of approximately 5% of 
known GPCRs[5,6]. 
 
Dopamine receptors (DRs) which are class A GPCRs, are characterized 
by an extracellular N-terminus containing several conserved cysteine 
residues, which stabilize the protein structure, and a very long 
intracellular C-terminus [7]. The C-terminus is involved in different 
signalling events in the cell and upon its phosphorylation the receptor is 
internalized via the β-arrestin pathway[8–10]. These receptors are 
prevalent in the central nervous system (CNS) and mediate several 
physiological functions such as voluntary movement, reward, hormonal 
regulation and hypertension[7,9,11]. Drugs targeting dopaminergic 
neurotransmission have been employed to treat several neurological and 
psychiatric disorders, including Huntington’s and Parkinson’s disease, 
schizophrenia, attention deficit hyperactivity disorder (ADHD) and 
Tourette’s syndrome[12]. DRs are also targets for studying drug abuse or 
addiction[9]. 
 
DRs are divided into two subfamilies, the D1 family (D1 and D5) and the 
D2 family (D2, D3, D4). Their assignment to either subfamily is based on 
their ability to modulate intracellular concentrations of cAMP. They are 
thought to be present in the membrane as monomers but also 
homodimers, heterodimers or tetramers, as evidenced by fluorescence 
and bioluminescence experiments using both in vivo and in vitro 
models[7,13–15]. As an example, the cross family hetero-oligomerization 
of D1 and D2 receptor is thought to play a role in drug addiction 
phenomena by re-programming the signalling transduction cascades. 
These receptors can also hetero-oligomerize with other GPCRs such as 
the opioid, cannabinoid, histamine or neurotensin receptors, making their 
individual study problematic due to their promiscuous interactions and 











Although DRs have been extensively studied for nearly 40 years 
(discovery of the first dopamine receptor was in 1975[19]), only a few 
crystal structures have been published to date (for D3[20], D4[21] and 
recently D2[22]) hampering efforts to fully elucidate the modes of ligand 
binding and therefore the design of more potent drugs or inhibitors. 
 
Indeed, the majority of the studies on DRs have been performed using in 
vitro models such as cell culture or animal tissues, fewer studies have 
been performed using detergent matrices, due to their poor stability in 
the detergent environment, evidenced by loss of function. Expression of 
sufficient quantities of functional receptor for biophysical characterization 
and crystallization is also a significant obstacle. Several approaches 
have been developed over recent years  in efforts to improve the 
expression of GPCRs, including the change of the host expression 
organism from bacterial to mammalian sources[23,24]; introduction of a 
soluble protein into the host sequence [23,25,26] either by adding a 
GFP-tag to one of the protein termini or by introducing T4 Lysozyme in 
one of the interhelix loops of the protein to promote crystal contacts for 
crystallography and even mutations of the protein sequence in order to 
obtain thermostabilized derivatives[27].  However, these approaches 
may have detrimental effects on ligand binding or signalling[28–30]. 
 
SMA polymer has recently emerged as  a useful new tool for 
simultaneous and nonselective extraction of lipids and embedded 
proteins present from biological membranes, whilst preserving protein 
structure and activity[31–36]. SMA nanoparticles have also been used 
for structural characterization by cryo-EM[37,38] and X-ray 
crystallography[39]. Several membrane proteins including ion 
channels[40] and GPCRs[41,42] have been studied and characterized 
from different organisms[43–46]. Proteomics and lipidomics experiments 
using SMALPs have also been performed using hydrogen-deuterium 
exchange mass spectrometry, MALDI-TOF MS/MS and using 
LC-MS/MS[47–50]. 
 
The potential to apply this approach to retain a non-thermostabilized 
receptor, expressed in a mammalian cell line, in a lipid composition 
wrested from its native environment is therefore scientifically very 
appealing. Here we show that the SMA polymer is a powerful tool to 
extract and purify membrane proteins expressed in HEK cells. The D1-
Lipodisqs are suitable for standard biophysical techniques such as 
circular dichroism, radio-ligand binding and microscale thermophoresis. 










nanoplatform for challenging receptors such as GPCRs, as they maintain 












2. Materials and Methods 
 
2.1 Wild-type human D1  
 
Dopamine receptor 1 (sequence can be found in SI) was expressed by 
UCB Celltech (Braine, Belgium). Briefly, cells were cultured at 37°C in a 
humidified atmosphere of 5% CO2. Cells were grown in DMEM F12+ 
GlutaMAX-I medium (GIBCO, Invitrogen, Merelbeke, Belgium) containing 
10% fetal bovine serum (FBS) (BioWhittaker, Lonza, Verviers, Belgium), 
400 μg/ml Geneticin (GIBCO, Invitrogen, Merelbeke, Belgium), 100 IU/ml 
Penicillin and 100 IU/ml Streptomycin (Pen-Strep solution, BioWhittaker, 
Lonza, Verviers, Belgium). HEK293f cells expressing the human 
dopamine receptor 1 were developed in house. Adherent cells were 
cultured in 175 cm2 Petri dishes until confluent, and the medium 
removed. The cells were washed with 30 mL phosphate buffered saline 
(PBS) at 25°C and detached by incubation with 30 mL of 1 mM EDTA 
solution in PBS (pH 7.4) for 7 minutes at 37°C, and centrifuged (1500g, 
10 min, 4°C).  
 
2.2 Membrane preparation 
 
Cell pellets (from 500 mL of culture) were resuspended in 3 mL of cold 
homogenization buffer (20 mM PBS pH 7.4, 2 mM EDTA, and 2 μL/mL of 
aprotinin, pepstatin and leupeptin protease inhibitors), and then dounce 
homogenized (100 strokes) on ice. The homogenate was centrifuged 
(1000g, 15 min, 4°C), and the resulting supernatant ultracentrifuged 
(40,000g, 1 h, 4°C). The resulting pellet was resuspended in buffer (50 
mM NaH2PO4, 200 mM NaCl, pH 8 and 2 μL/mL of aprotinin, pepstatin 
and leupeptin protease inhibitors) using a 25-gauge needle (100 
passes). The total c ncentration of protein was determined by BCA 
assay. Resuspended membranes were either directly used for Lipodisq 
formation or flash frozen in liquid nitrogen or stored at -80°C. 
 
2.3 SMA hydrolysis 
 
Styrene-maleic anhydride polymer (SMAnh, kindly provided by Malvern 
Cosmeceutics) in a ratio of styrene to maleic anhydride of 3:1, was 
hydrolysed by adding 1M NaOH solution (5% w/v final) (Fisher), heated 
at 80-90°C for 1-2 h. 5 M HCl was then added to precipitate the SMA, 
which was pelleted by centrifugation (2000g, 5 min, RT). Pellet was 
re-solubilised in water and subjected to multiple washing (3-5 times) and 
centrifugation steps (2000g, 5 minutes). Once washed, double distilled 










overnight in order to remove the excess of salt and to adjust the pH. At 
this stage, the SMA should be a clear yellowish solution and to further 
concentrate it, lyophilization was performed. A white powder was 
collected and weighted. ddH2O water or buffer was added to a final 
concentration of 125 mg/ml and pH adjusted to pH 8.  
 
2.4 Lipodisqs formation and purification 
 
Lipodisqs were formed by directly adding the copolymer (styrene-maleic 
acid, SMA) 3:1 pH 8 to the previously prepared membranes, at a 
membrane:SMA w/w ratio of 1:1.5. Sample was left to incubate (8 h, 
4°C) in a rotating wheel in 50 mM NaH2PO4, 200 mM NaCl, pH 8. To 
remove non-solubilized membrane particles and any aggregated 
material, ultra-centrifugation was performed (100,000g, 40 min, 4°C) 
prior to size exclusion chromatography. The supernatant was subjected 
to SEC on a Superdex 200 Increase 10/300 GL (GE Healthcare) to 
remove excess polymer. Fractions from size exclusion chromatography 
(from 9 mL to 13 mL elution volume) were collected and applied to a 5 
mL HisTrap HP (GE Healthcare) column previously equilibrated in 50 
mM PBS buffer. Samples were recirculated through the column at 1.5-2 
mL/min for 1-2 hours at 4°C. For elution, increasing concentration of 
imidazole in binding buffer were employed, using 2 column volumes per 
concentration gradient. Elution peak appeared between 50 to 500 mM 
imidazole. D1-Lipodisqs were concentrated using a 100k MWCO 
Vivaspin20 tube (Greiner) and buffer-exchanged to PBS.  
 
2.5 Radioligand binding assays 
 
The determination of the amount of active receptor was carried out by 
radioligand binding assays on HEK293f D1 membrane samples and D1 
contained Lipodisq. The D1 selective antagonist N-methyl-[3H]-SCH 
23390 was used as radioligand (81.9 Ci/mmol, PerkinElmer). For 
saturation studies, 5 different concentrations of radioligand (in duplicates 
or triplicates) were used within the 0.2-5 nM range, in 50 mM NaH2PO4, 
2 mM MgCl2, 100 mM NaCl buffer at pH 7.4 (avoiding MgCl2 for Lipodisq 
samples). Protein amount used was 5 μg total protein per sample. 
Non- specific binding was assayed by competition with excess (10 μM) of 
unlabelled D1 selective antagonist (+)-butaclamol. All samples were 
incubated for 1 hour at room temperature for maximum receptor 
saturation. For the membrane assays, the bound ligand was separated 
from the free radioligand by rapid vacuum filtration through GF/B or GF/C 
glass microfiber filters presoaked in polyethyleneimine (PEI) 0.3% for 1 










with 2 mL ice-cold 50 mM NaH2PO4 buffer pH 7.4. For Lipodisq samples, 
the separation was carried out using pre-equilibrated P-30 spin columns 
(Bio-Rad). Scintillation liquid (3 mL) (ScintiSafe 3 Liquid Scintillation 
Cocktail, Fisher Scientific) was added to the bound sample and 
radioactivity was measured in dpm on a scintillation counter (1409 DSA 
Liquid Scintillation Counter, PerkinElmer). Specific binding was 
determined by subtracting the non-specific dpm from the total dpm. 
 
2.6 Microscale thermophoresis experiment (MST) 
 
Microscale thermophoresis experiments were performed on a blue/red 
Monolith NT.115 instrument (NanoTemper Technologies). A typical 
experiment is carried using a dilution series (10-15 points) of the 
unlabelled binding partner. LoBind tubes were used to ensure minimal 
adsorption of the sample in the reaction tubes. Capillary scans were 
performed to ensure that fluorescence was constant (within ± 10%) 
within the tubes. The fluorescently labelled ligand Cy5-neurotensin 
(Cy5-NT) was prepared in 20 mM phosphate buffer 200 mM NaCl pH 8 
at the desired concentration (from 0.05 nM to 1 µM). Samples were 
incubated at 20°C for 30 minutes in binding buffer after which they were 
loaded into Standard Treated capilla ies (NanoTemper Technologies). 
Thermophoresis was measured at different MST power (20, 40, and 
80%), with 80% giving the best results. To account for the non-specific 
signal, two control experiments were accomplished, one consisting in 
boiling the LQs samples at 100°C for 10 min, and the other measuring 
the thermophoresis of LQs prepared from non-transfected HEK293 
membranes. The MST data was analysed and the KD was calculated 











3. Results and Discussion 
 
3.1 Preparation, purification and characterisation of D1 Lipodisqs  
 
The solubilization of the membrane protein was performed by the 
addition of an excess of polymer to the membrane in a 1:1.5 
weight-to-weight ratio as described in the literature[31,34]. The time of 
incubation of the polymer-membrane mixture was chosen to be 1-2 h at 
4°C in order to keep the protein fold intact during the extraction. 
Although, longer incubation times or higher temperatures could be used 
for solubilizing membrane proteins from the membrane environment, this 
can be detrimental to protein folding and activity[31,34,51]. In a few  
literature examples this solubilization step is performed at room 
temperature for an extended time, such as for chromatophore (1h at 
20°C[45]), complex IV (30 minutes at 25°C[46]) and for the A2a model 
GPCR in yeast and HEK cells (20h at 20°C[41]). In our case, we chose 
not to follow the same experimental procedure of Jamshad et al.[41] , as, 
when compared to A2a for which ligand binding data suggests that the 
protein retains activity above room temperature, there is no data 
available for D1 concerning its stability at room temperature or above. 
Therefore, we decided to keep the temperature as low as possible whilst 
the SMA incubation time was increased up to 8 hours to maximize the 
formation of the Lipodisqs at low temperature. 
 
It is important to highlight that the buffer used for membrane 
solubilization by SMA should contain between 100-300 mM NaCl, as salt 
allows the polymer to deposit on the membrane by shielding the 
electrostatic repulsion between SMA and negatively charged lipids, and 





Figure 1 Schematic representation of how to purify membrane proteins 
using SMA. First, SMA is added to the host membrane, which form 
proteo-Lipodisq. Excess of SMA is removed via SEC and finally 















Once the samples were solubilized, any non-solubilized materials and/or 
aggregates were removed by ultra-centrifugation. The supernatant was 
subjected to size-exclusion chromatography to remove the excess of free 
polymer prior to IMAC purification (Figure 1 and 2). Free SMA must be 
removed for two main reasons: (i) the excess of polymer would unduly 
complicate the biophysical characterisation of the proteins in Lipodisqs 
(by CD, for example), and (ii) the maleic acid moiety of SMA would 
compete with the protein His-tag in binding to the metal ions of the IMAC 




Figure 2 Size-exclusion profile of D1-Lipodisq on a Superdex 200 
Increase, where proteo-Lipodisqs elute between 8.5-13 mL. Free SMA 
elutes at 20-22 mL. Here the aggregation peak has been collected and 
not discarded since higher oligomeric states of the protein could be 
present in the void volume of the column.  
 
A typical SEC elution profile is shown in Figure 2. Here, all the samples 
from the elution volumes 8.5 mL to 13 mL were collected, including the 










discarded. DRs have been observed in several different oligomeric 
states as monomer, dimers or tetramers[14,53–55] and as the oligomeric 
state would have an impact on the final Lipodisq size we chose not to 
exclude any fractions at this stage. 
 
Once the excess polymer had been removed, the samples were purified 
by IMAC using a HisTrap column. Samples were recirculated through the 
column, as a single pass yielded only a small amount of receptor due to 
the large size of the Lipodisq, impeding the interaction between the metal 
ion and the HisTag[34]. A low flow rate and several passes through the 
column accentuate the interaction between the ion metal and the HisTag 
as shown by Pollock and colleagues[34,56]. The temperature at which 
the purification was performed (4°C) was again chosen to ensure protein 
stability. Elution of the protein was performed by increasing the imidazole 
concentration in steps of 25 mM, 50 mM, 100 mM and 250 mM (Figure 
3). The 25 mM imidazole clean-up step elutes any non-specific protein 
bound to the column, hence the multiple bands present in the 
corresponding SDS-PAGE gel lane in Figure 3. The 50 mM imidazole 
step was intended to initiate the elution of the protein, but no gel bands 
were observed corresponding to the protein of interest. At high imidazole 
the protein elutes with high purity as shown in the gel lanes on the right 
in Figure 3. The yield of the purification was calculated using BCA assay 
and estimate to be 0.255 mg/L of culture. This is somewhat similar to the 
yield obtained in the literature[56,57]. Silver stain was used to ensure 
that the protein had not co-eluted with any impurities. We speculate that 
the high molecular weight species present is a dimer of the D1 protein. 
Next, to confirm that no other protein was present in our sample, western 











of  Figure 3 SDS-PAGE gels from D1 Lipodisq IMAC purification. Protein of 
interest (marked with *) is typically eluted at concentration higher than 50 
mM imidazole and is relatively pure at high concentration of imidazole.  
 
The presence of the protein was verified by western blot analysis as 
shown in Figure 4. For the D1-LQ sample, enhanced chemiluminescence 
(ECL, see Supplementary information for experimental details) was 
performed as the quantity of purified receptor was low (< 1 µM). An 
anti-His antibody and the D1 specific Fab antibody fragment both reveal 
a band at the expected molecular weight of the protein, confirming that 
the protein has been purified. 
 
 
Figure 4 Western blots for D1 Lipodisq samples. Anti-His and D1-Fab 
reveal the presence of the D1 receptor in the sample purified after IMAC 
at the expected molecular weight of the receptor and correlates with the 
band observed in the SDS-PAGE. FT: Flow through; a: 25 mM imidazole 
fractions; b: 250 mM imidazole fractions 
 
Due to the small amount of receptor purified, to further confirm that D1 
was present in the Lipodisqs after the IMAC purification by an orthogonal 
method, proteomics experiments were performed by LC/MS/MS (Table 
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derived from the C-terminus, the intracellular loop 3 and the extra-cellular 
loop 2 confirming that D1 was purified in the Lipodisq via SMA 
solubilization.  
 
Table 1 Peptides identified from the proteomics experiments on D1 
Lipodisq samples. 
Unique peptides of hs-D1 sequence identified 
EEAAGIARPLEK C-terminus 
NCQTTTGNGKPVECSQPESSFK Intracellular loop 3 
AKPTSPSDGNATSLAETIDNCDSSLSR Extra-cellular loop 2 
 
3.2 Radio-ligand binding assays  
 
Before assessing the activity of the receptor, the folding of the protein 
was studied using circular dichroism (Figure S1). The CD data reveal 
that the D1 fold is retained in the Lipodisq. The affinity properties of the 
D1 protein reconstituted into LQ was confirmed by radio-ligand binding 
(Figure S2). The binding affinity of the protein in native HEK293f cell 
membranes was established by using the specific D1 antagonist, 
SCH23390 and the level of non-specific binding was assessed using 
(+)-butaclamol[58,59]. The data (Figure S2) reveals that the protein is 
able to bind ligands in both the native membrane and in Lipodisqs. 
Importantly, the binding affinity and receptor density (Bmax) of SCH23390 
was similar for D1 Lipodisqs and D1 HEK membranes, which confirms 
that the protein binding affinity is maintained during the SMA-LQ 
extraction from the membrane.  
 
Similar results have been observed for the adenosine receptor (A2a)[41], 
which was extracted from HEK cells using SMA. Jamshad et al. showed 
that A2a in SMALPs display similar binding affinity to the receptor from 
HEK membranes. This observation suggests that SMA is a suitable new 
alternative for membrane protein purification enabling the study of the 
different GPCR signalling pathways in a more native environment than 
the detergent setting. To emphasise how crucial the protein-lipid 
environment is for ligand binding or protein signalling, it has been 
demonstrated that dopamine receptors, upon interaction with certain 
drugs such as cocaine, are able to translocate to a different lipid 
environment[60,61]. Thus, the ability to directly extract proteins in their 
preferred local lipid composition using SMA Lipodisqs may offer 
significant advantages over current approaches. 
 
3.3 Microscale thermophoresis experiments reveal the interaction 











Several in vivo studies have highlighted the possible interaction between 
neurotensin and dopaminergic system[62]. It has been shown that the 
neurotensin peptide (NT) can modulate dopamine release in various 
brain structures[63–68], and that NT and dopamine (DA) colocalize in 
certain compartments of the brain[69,70]. In addition, NT can regulate 
the dopaminergic transmission in certain tissues[62,68].  
 
Herein, we have demonstrated using microscale thermophoresis that, in 
vitro, neurotensin is able to bind specifically to the purified D1 embedded 
into Lipodisqs. We hypothesize that the stable and native lipid 
environment provided by the Lipodisq produces the ideal environment for 




Figure 5 MST titration assays. Binding affinity experiments were 
conducted using labelled NT (NT-Cy5). The affinity of NT-Cy5 for D1 
Lipodisqs was > 300 nM. Denatured D1 Lipodisq and Lipodisq formed 
from HEK cells lacking D1 (red and green curves respectively) did not 
show binding to NT. Error bars represent the standard error of n=3 
measurements.  
As it can be observed in Figure 5, the interaction between NT and D1 in 
Lipodisq is clear. Moreover, the binding is only due to the presence of D1 
receptor in the discs since the two performed controls evidence that 
neither the lipids nor the polymer or other proteins present in the HEK 
plasma membrane interact with NT (red and green curve in Figure 5). 
Unfortunately, we were not able to reach receptor saturation therefore 
we cannot reliably calculate the affinity of NT-D1 receptor binding. 
However, we can estimate that it is higher than 300 nM. Although this 






























receptor (KD=9 nM)[8,62] and also lower than the affinity of NT for other 
neurotensin receptors (KD=0.1-10 nM)[62,71] it is none-the-less in a 
biologically relevant range. Hence, to the best of our knowledge, we 
report the first evidence of a specific interaction in vitro between NT and 




We report for the first time the use of SMA copolymer for extraction and 
purification of a wild-type human GPCR from its native lipid environment 
via detergent-free Lipodisq formation. Proteomics and western blot 
experiments confirm the presence of the receptor after purification, while 
radioligand binding confirms that the binding affinity of the receptor is not 
affected after SMA solubilization. Importantly, we showed for the first 
time the existence of binding of the neurotransmitter neurotensin to D1 
receptor, an interaction that might have important biological implications 
as dopamine receptors have been shown to form heterodimers with 
neurotensin receptor 1 (NTS1)[72–74]. Our work paves the grounds for 
the purification and characterisation of wild-type GPCRs in their 
functionally relevant lipid environment. This is of key importance in 
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 We report for the first time the extraction and purification of a 
wild-type human GPCR from its native lipid environment via 
detergent-free Lipodisq formation.  
 It is the first time that microscale thermophoresis is used to perform 
ligand binding for protein embedded in Lipodisq. 
 We prove for the first time the existence of binding of the 
neurotransmitter neurotensin to D1, an interaction that might have 
important biological implications.  
Journal Pre-proof
